IRONWOOD PHARMACEUTICALS, INC. Purchase AgreementPurchase Agreement • June 15th, 2015 • Ironwood Pharmaceuticals Inc • Pharmaceutical preparations • New York
Ironwood Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $300,000,000 aggregate principal amount of its 2.25% Convertible Senior Notes due 2022 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $45,000,000 aggregate principal amount of its 2.25% Convertible Senior Notes due 2022 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such Option Securities pursuant to the terms of Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”.
